“The CareDx sessions at the EFI meeting this year will tackle innovative subjects in the field of Immunogenetics and Transplantation, which will have great impact on improving patient care and transplant outcomes!” said Moheeb Al-Awwami, Director, Histocompatibility and Immunogenetics Laboratory, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
The second symposium,
Donor-Derived Cell-Free DNA as Biomarker to Assess Active Rejection & Treatment Response in Kidney Allografts – Caner
Su
sal, University of Heidelberg, Germany
Value of dd-cfDNA as a Surveillance Biomarker in Heart Transplant – Maria Generosa Crespo-Leiro, Complexo Hospitalario Universitario A Coruña (CHUAC), Spain
Quality Approach and Adoption of NGS based Chimerism Solution in a French Laboratory – Mathilde Cherel, EFS Rennes, Blood Bank of Brittany, France
CareDx Showcases Transplantation Innovation and Leadership in Europe at EFI 2021Virtual Events to Highlight New Data and AlloSeq Solutions for European Labs and Clinicians biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Share this article
LAS VEGAS, March 11, 2021 /PRNewswire/ DelveInsight s
Treatment-Resistant Depression (TRD) Market report provides a thorough comprehension of the Treatment-Resistant Depression, historical and forecasted epidemiology, and the TRD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Treatment-Resistant Depression market report also proffers an analysis of recent Treatment-Resistant Depression treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the vital points of the
The FDA approved
SYMBYAX for acute treatment of TRD and depressive episodes associated with Bipolar Disorder in adults in March 2009.
In March 2019, the FDA approved
Background
There have been dramatic changes in the treatment of rheumatoid arthritis (RA) in the last 20 years with the introduction of hugely effective new classes of drugs (Biologics) and with a more aggressive treatment at an early stage to limit the damaging inflammatory process of this disease. However, in the midst of all these exciting medical advances there is still a big question that has not yet been solved - which patients will respond best to which drugs? Current treatment is still a frustrating process of trial and error for the patient with potential unwanted side-effects, joint damage and worse outcomes, a reality of the waiting process.
Soligenix Announces Investor Webcast Event: U S Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.